Adjuvant therapy with zoledronic acid to prevent bone metastases in patients with lung cancer: a prospective, randomized, controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PPR-15007009

Enrollment

Unknown

Registered

2015-09-03

Start date

2015-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

experimental group:zoledronic acid

control group:none

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. patients with primary lung cancer,identified by histopathological examinations; 2. age between 18 and 70.

Exclusion criteria

Exclusion criteria: 1. with other malignancy besides lung cancer; 2. expected survival time is less than 6 months; 3. identified existence of bone metastases; 4. with controindications of zoledronic acid; 5. patient refusal.

Design outcomes

Primary

Measure	Time frame
incidence of bone metastasis;	—

Secondary

Measure	Time frame
survival time;incidence of skeletal related events;	—

Countries

China

Contacts

Public ContactSong Weian

18600310961@126.com+86 18600310961

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026